Previous close | 0.0156 |
Open | 0.0058 |
Bid | 0.0232 x N/A |
Ask | 0.0454 x N/A |
Day's range | 0.0058 - 0.0156 |
52-week range | 0.0002 - 0.0810 |
Volume | |
Avg. volume | 0 |
Market cap | 13.835M |
Beta (5Y monthly) | -0.22 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announced that remaining commitments for the company have been quantified, and the expected cash balance per March 31, 2024, amounts to SEK 180-190 million.
InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.
InDex Pharmaceuticals Holding AB (publ) today announced that 30% of patients have completed the final visit in Induction Study 1 of the phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis. The outcome of the cobitolimod dose selection analysis will be presented in Q4 this year according to plan.